✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Different receptors entirely. Semaglutide is a GLP-1 agonist (hypothalamic / vagal satiety). Cagrilintide is an amylin analogue (hindbrain amylin receptors). Non-overlapping pathways.
- Complementary rather than competitive. The headline research finding is the CagriSema combination: -15.7% at 32 wk vs -8.1% for semaglutide alone at the matched dose. Additive without proportional GI-side-effect amplification.
- Cagrilintide standalone is rarely the research question. Most published research is in the CagriSema combination framing rather than cagrilintide monotherapy.
- Long half-lives on both molecules support weekly dosing. Cagrilintide is acylated for albumin binding, mirroring semaglutide’s pharmacokinetic strategy.
- This guide compares the two on mechanism, dosing, and how they combine in research-protocol design.
Cagrilintide vs Semaglutide: Amylin Analogue vs GLP-1 Agonist and the CagriSema Stack
These two molecules answer a different question than the receptor-architecture comparisons within the incretin family. Cagrilintide and semaglutide work through fundamentally different physiological pathways — amylin signalling and GLP-1 signalling — and the most-cited research finding is not which molecule wins standalone, but how they combine. This guide covers both the standalone comparison and the combination (“CagriSema”) research.
Quick verdict
- Standalone weight-loss research: Semaglutide (deeper standalone effect; established mechanism).
- Combination research: CagriSema. The two molecules’ non-overlapping mechanisms make them the cleanest combination in the modern obesity-pharma literature.
- Pure amylin-mechanism research: Cagrilintide standalone. Rarely used outside the CagriSema framing but valid for amylin-receptor pharmacology research.
Mechanism: amylin vs GLP-1
GLP-1 (glucagon-like peptide-1) is the most-researched satiety hormone. Semaglutide is the long-acting GLP-1 receptor agonist that defined the modern obesity-pharma class. The mechanism operates through hypothalamic GLP-1 receptors (driving the central satiety signal), peripheral GLP-1 receptors in the GI tract (slowing gastric emptying), and vagal afferent signalling (reinforcing the satiety circuit). Effect size in STEP-1: -14.9% at 68 wk at the 2.4 mg weekly dose.
Amylin is a pancreatic hormone co-secreted with insulin from beta cells. Its primary action is at hindbrain amylin receptors (specifically the area postrema), where it produces a different kind of satiety signal — slower onset, longer duration, and a meal-termination effect distinct from the appetite-suppression mechanism of GLP-1. Cagrilintide is a synthetic amylin analogue with structural modifications (including acylation for albumin binding) that extend half-life to ~8 days, supporting weekly dosing.
The cleanness of the combination logic: GLP-1 acts on hypothalamic and gastric satiety circuits; amylin acts on hindbrain meal-termination circuits. The two are non-overlapping enough that combined dosing produces additive weight loss without the side-effect amplification that would occur if both were activating the same GI / gastric-emptying pathway.
The CagriSema Phase 2 finding
The headline research data is the REDEFINE Phase 2 trial (and its successor Phase 3 program). At the 2.4 mg cagrilintide + 2.4 mg semaglutide combination dose, mean weight loss reached -15.7% at 32 weeks — compared with -8.1% for semaglutide 2.4 mg alone at the matched 32-week time point. Cagrilintide monotherapy at 2.4 mg produced -8.0% in the same comparison — effectively matched to semaglutide standalone.
The combination effect is therefore close to additive but slightly less than perfect addition (-15.7% vs -16.1% theoretical sum). The published GI-side-effect comparison shows nausea rates broadly similar to semaglutide standalone — the additive weight-loss effect comes without proportional additive nausea, the defining mechanistic finding.
Comparison table
| Property | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor | Amylin receptor (calcitonin family) | GLP-1 receptor |
| Primary site of action | Hindbrain (area postrema) | Hypothalamus + GI tract + vagal afferents |
| Mechanism description | Meal-termination satiety | Appetite suppression + gastric emptying |
| Half-life | ~8 days | ~7 days |
| Comparator drug | None (Phase 3 in CagriSema) | Ozempic / Wegovy / Rybelsus (FDA-approved) |
| Standalone effect (matched 32 wk) | ~-8.0% at 2.4 mg | ~-8.1% at 2.4 mg |
| Combination effect (CagriSema) | -15.7% at 32 wk | |
Which to pick (research-protocol logic)
- Standalone weight-loss research: Semaglutide. Established mechanism, longer trial duration, FDA-approved comparator drugs.
- Standalone amylin-pharmacology research: Cagrilintide. The reference long-acting amylin analogue. Rarely used standalone but valid for amylin-receptor mechanism research.
- Combination obesity-pharma research: Both, in the CagriSema framing. The cleanest non-overlapping mechanism combination in the modern obesity-pharma literature.
- Comparing combination architectures: CagriSema vs retatrutide as standalone triple agonist — the two main approaches to “deeper than GLP-1-mono” obesity pharmacology.
Safety and regulatory status
Semaglutide’s comparator drugs (Ozempic / Wegovy / Rybelsus) are FDA-approved; the research-grade lyophilized peptide is not the finished pharmaceutical product. Cagrilintide has no FDA-approved comparator; the CagriSema combination is in Phase 3 development. The research-grade compounds are sold for in-vitro laboratory research and analytical reference use only. Class-level safety considerations include GI side effects, gallstone risk with rapid weight loss, and amylin-specific considerations including bradygastria and theoretical effects on bone mineralisation in long-duration animal studies. None of this is medical advice.
FAQ
What does “CagriSema” actually contain?
The Phase 3 CagriSema combination contains cagrilintide (the amylin analogue) plus semaglutide (the GLP-1 agonist) at matched 2.4 mg weekly doses. The Phase 3 trials evaluate the fixed-combination product; the Phase 2 REDEFINE trial compared cagrilintide standalone, semaglutide standalone, and the combination arm.
Why does amylin add so much on top of GLP-1?
Because the two hormones drive non-overlapping satiety pathways. GLP-1 acts on hypothalamic and gastric circuits (appetite and gastric emptying). Amylin acts on hindbrain meal-termination circuits (a different signal type, slower onset, longer duration). Activating both pathways together produces additive weight loss without the side-effect amplification that would occur if both were targeting the same circuit.
Is CagriSema better than retatrutide?
Direct head-to-head data does not yet exist. Indirect comparison from Phase 2 readouts at matched 32-48 week windows: CagriSema -15.7% at 32 wk vs retatrutide -24.2% at 48 wk. Retatrutide appears deeper at the longer timeframe; the matched 32-week point would need direct comparison. CagriSema and retatrutide are the two leading “deeper than GLP-1-mono” approaches: one via combination (CagriSema), one via triple agonism (retatrutide).
Can cagrilintide be used standalone?
Yes, for research-protocol purposes — cagrilintide as monotherapy has documented amylin-receptor pharmacology effects. At standalone 2.4 mg the weight-loss effect is comparable to semaglutide 2.4 mg (around -8% at 32 wk). The CagriSema framing is the primary research direction not because cagrilintide standalone is ineffective but because the combination is more interesting from both a development and a clinical-positioning perspective.
What’s the dosing protocol for the combination?
Phase 3 CagriSema dose: 2.4 mg cagrilintide + 2.4 mg semaglutide, weekly SC, after appropriate titration on the semaglutide arm. The titration profile mirrors semaglutide’s standard ladder.
How is amylin’s mechanism different from glucagon’s?
Different physiological signals entirely, despite both being pancreatic hormones. Amylin is co-secreted with insulin from beta cells and produces a meal-termination satiety signal via hindbrain receptors. Glucagon is secreted from alpha cells in response to hypoglycaemia and produces hepatic glucose mobilisation. Glucagon-arm activation (as in retatrutide) increases basal metabolic rate; amylin-arm activation (as in cagrilintide) deepens satiety. Different mechanisms; different downstream effects.
What’s the storage protocol?
Standard peptide storage: lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Bottom line
Semaglutide and cagrilintide are mechanistically distinct molecules whose primary research interest in 2026 is their combination rather than their individual standalone performance. The CagriSema combination produces additive weight loss (-15.7% at 32 wk) without the side-effect amplification that would normally accompany dose escalation within a single mechanism class. For research-protocol design, semaglutide is the GLP-1 baseline and cagrilintide is the amylin baseline; the combination is the most-published “deeper than monotherapy” approach in the modern obesity-pharma literature. The competing approach is retatrutide’s triple-agonist architecture — see the 3-way comparison for that contrast.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.